Why the study?
Does proton-decoupled P-31 MR spectroscopy detect abnormalities in cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy compared to healthy subjects?
Does proton-decoupled P-31 MR spectroscopy detect abnormalities in cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy compared to healthy subjects?
Answers are grounded in this paper and cite their sources.
Proton-decoupled P-31 MR spectroscopy can detect metabolic abnormalities, including altered PCr/ATP ratios and myocardial pH, in patients with hypertrophic and dilated cardiomyopathy.
Proton-decoupled phosphorus-31 heart spectroscopy was performed in healthy subjects (n = 9) and patients with dilated cardiomyopathy (DCM, n = 9) or hypertrophic cardiomyopathy (HCM, n = 8). The phosphocreatine (PCr)-to-adenosine triphosphate ratio (+/- one standard deviation) after correction for blood contribution and partial saturation was significantly lower in HCM patients relative to the control subjects (1.32 +/- 0.29 vs 1.65 +/- 0.26, P < .05) but not in DCM patients (1.52 +/- 0.58 vs 1.65 +/- 0.26). The inorganic phosphate (Pi) peak was resolved only in patients with the highest spectral quality. Myocardial pH was lower in HCM patients (n = 6) relative to control subjects (n = 4) (7.07 +/- 0.07 vs 7.15 +/- 0.03, P < .05). The Pi/PCr ratio was higher in DCM (n = 3) and HCM (n = 6) patients relative to control subjects (n = 4) (0.29 +/- 0.06 and 0.20 +/- 0.04, respectively, vs 0.14 +/- 0.06; P < .05). Elevated phosphodiester signal in DCM patients correlated with 2,3-diphosphoglycerate signal (r = .94), reflecting blood pool contamination. P-31 spectroscopy enabled detection of abnormalities in cardiac metabolism and determination of pH in patients with HCM and DCM.
No takes yet. Share an insight, caveat, or question.
Roos et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: